Subscribe to receive future Ambry updates!
Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
Ambry Genetics Data Supports Functional Study of BRCA2 Helping Improve Variant Classification for Hereditary BRCA2-Linked Cancers
Ambry Genetics Expands Its Award Collection with Three New Comparably Best Place to Work Honors for 2024
Letter from Tom Schoenherr, CEO: Definitive Agreement for Acquisition of Ambry Genetics by Tempus AI
Ambry Genetics Announces New Hereditary Cancer Test Menu at NSGC Annual Conference
Ambry Genetics Announces New Multiomic Exome Test for Improved Rare Disease Detection
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologists
Ambry Genetics Unveils at ASHG New Insights on the Use of Multiomic Testing in 43,000 Patient Study
Start your search...